|
Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP). |
|
|
Employment - Genentech/Roche (I); Macrogenics (I) |
Stock and Other Ownership Interests - Genentech (I); Sema4 |
Consulting or Advisory Role - Astellas Pharma; Sema4; Takeda; VieCure |
Research Funding - Kiadis Pharma (Inst); Sema4 (Inst); Takeda (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Takeda (Inst) |
|
|
Research Funding - Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - AstraZeneca/Merck (Inst) |
|
|
|
Stock and Other Ownership Interests - Sema4 |
|
|
|
Stock and Other Ownership Interests - Sema4 |
|
|
|
|
Stock and Other Ownership Interests - Sema4 |
Consulting or Advisory Role - Berg |
Research Funding - GlaxoSmithKline; Janssen; Lilly; Sanofi; Sema4 |
|
Luis Alexander Rojas-Espaillat |
No Relationships to Disclose |
|
|
|
Leadership - NantWorks; Vincerx Pharma |
Stock and Other Ownership Interests - NantWorks |
Consulting or Advisory Role - Vincerx Pharma |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Conjupro Biotherapeutics; Foundry; HUYA Bioscience International; Janssen; Sanofi; Sema4; TeneoBio |